Lupin Receives U.S. FDA Approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

Global pharma major Lupin Limited (Lupin) today announced that it has received approval for its Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Truvada® Tablets, 200 mg/300 mg, of Gilead Sciences, Inc. The product will be manufactured at Lupin's facility in Nagpur, India.

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. It is also used for for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets(RLD: Truvada®) had estimated annual sales of USD 2.1 billion in the U.S. (IQVIA MAT March 2021).

Shares of LUPIN LTD. was last trading in BSE at Rs.1231.35 as compared to the previous close of Rs. 1232.35. The total number of shares traded during the day was 77473 in over 3206 trades.

The stock hit an intraday high of Rs. 1249.8 and intraday low of 1223.6. The net turnover during the day was Rs. 95635682.

Source : Equity Bulls

Keywords